Cargando…

Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with poor outcomes in patients ineligible for autologous stem cell transplantation. In this setting, novel treatment approaches are urgently required and the innovative agent pixantrone has shown some promising res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Novakovic, Aleksander, Boltezar, Lucka, Novakovic, Barbara Jezersek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039066/ https://www.ncbi.nlm.nih.gov/pubmed/32194699 http://dx.doi.org/10.3892/ol.2020.11288

Ejemplares similares

Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
por: Jezeršek Novaković, Barbara, et al.
Publicado: (2021)

Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma
por: Boltežar, Lučka, et al.
Publicado: (2018)

CD56-positive diffuse large B-cell lymphoma: comprehensive analysis of clinical, pathological, and molecular characteristics with literature review
por: Gasljevic, Gorana, et al.
Publicado: (2023)

Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
por: Horvat, Matej, et al.
Publicado: (2018)

Granulomatosis after autologous stem cell transplantation in nonHodgkin lymphoma – experience of single institution and a review of literature
por: Boltezar, Lucka, et al.
Publicado: (2016)

Fertility in young patients following treatment for Hodgkin’s lymphoma: a single center survey
por: Boltežar, Lučka, et al.
Publicado: (2015)

Correlation of t(14;18) translocation breakpoint site with clinical characteristics in follicular lymphoma
por: Panjan, Matej, et al.
Publicado: (2023)

Long-term outcomes of high dose treatment and autologous stem cell transplantation in follicular and mantle cell lymphomas – a single centre experience
por: Boltezar, Lucka, et al.
Publicado: (2016)

Trends in specialized palliative care referrals at an oncology center from 2007 to 2019
por: Boltezar, Lucka, et al.
Publicado: (2021)

Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome
por: Rozman, Samo, et al.
Publicado: (2017)

The diffuse large B-cell lymphoma – where do we stand now in everyday clinical practice
por: Gregoric, Brigita, et al.
Publicado: (2012)

Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma
por: Novakovic, Barbara Jezersek
Publicado: (2015)

The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
por: ROŽMAN, SAMO, et al.
Publicado: (2016)

Diagnostic value of immunoglobulin κ light chain gene rearrangement analysis in B-cell lymphomas
por: KOKOVIC, IRA, et al.
Publicado: (2014)

Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma
por: Horvat, Mateja, et al.
Publicado: (2010)

Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas
por: Volpetti, Stefano, et al.
Publicado: (2014)

Treatment outcomes and survival in patients with primary central nervous system lymphomas treated between 1995 and 2010 – a single centre report
por: Jezersek Novakovic, Barbara
Publicado: (2012)

The predictive significance of CD20 expression in B-cell lymphomas
por: Prevodnik, Veronika Kloboves, et al.
Publicado: (2011)

Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma
por: Rožman, Samo, et al.
Publicado: (2022)

Patients’ decision-making, experiences and preferences regarding pixantrone treatment in relapsed or refractory diffuse large B-cell lymphoma: study protocol for a longitudinal mixed methods study
por: van Hoogdalem, Lothar E, et al.
Publicado: (2019)

An interesting case of likely BRCA2 related bilateral breast cancer with metastasis in the fimbrial part of fallopian tube
por: Boltežar, Lučka, et al.
Publicado: (2020)

Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision
por: Unk, Mojca, et al.
Publicado: (2023)

Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity
por: Cerkovnik, Petra, et al.
Publicado: (2010)

Clonality analysis of lymphoid proliferations using the BIOMED-2 clonality assays: a single institution experience
por: Kokovic, Ira, et al.
Publicado: (2014)

Pixantrone beyond monotherapy: a review
por: Barrenetxea Lekue, Cristina, et al.
Publicado: (2019)

Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Shu-Bei, et al.
Publicado: (2019)

Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial
por: Pettengell, Ruth, et al.
Publicado: (2016)

Pixantrone Sensitizes Gram-Negative Pathogens to Rifampin
por: She, Pengfei, et al.
Publicado: (2022)

Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
por: Krawczyk, Katarzyna, et al.
Publicado: (2014)

Management of relapsed-refractory diffuse large B cell lymphoma
por: Raut, Lalit S., et al.
Publicado: (2014)

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Harris, Leonard Jeff, et al.
Publicado: (2020)

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020)

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)

A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma
por: Thuresson, Per-Olof, et al.
Publicado: (2020)

Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
por: Goto, Hideki, et al.
Publicado: (2020)

Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma
por: Park, Ha Young, et al.
Publicado: (2016)

Outcome of severe infections in afebrile neutropenic cancer patients
por: Strojnik, Ksenija, et al.
Publicado: (2016)

Evolution of therapy for limited stage diffuse large B-cell lymphoma
por: Rojek, Alexandra E., et al.
Publicado: (2022)

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
por: Desai, Sanjal H., et al.
Publicado: (2022)

Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma
por: Hamlin, Paul A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2o958ngsn7jkeoji9l2pea3d3g